Merck kills Tredaptive worldwide
This article was originally published in Scrip
Executive Summary
Merck & Co is withdrawing its troubled dyslipidemia drug Tredaptive (niacin plus laropiprant) in all markets where it is available. The decision comes the same day that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee decided that the product's risks outweighed its benefits and recommended its suspension.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.